Details of the Drug
General Information of Drug (ID: DMM41AQ)
| Drug Name |
6-Chloro-2-piperazin-1-yl-quinoline
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
6-chloro-2-piperazin-1-yl-quinoline; 78060-46-5; 6-Chloro-2-(piperazin-1-yl)quinoline; 6-chloro-2-piperazin-1-ylquinoline; 6-chloro-2-(1-piperazinyl)quinoline; CHEMBL290537; AC1Q3JZ5; 2-Piperazino-6-chloroquinoline; SCHEMBL4182196; CTK5E5334; DTXSID60437575; GSFXEINORRSYJW-UHFFFAOYSA-N; ZINC2527450; 3506AJ; BDBM50090216; AKOS022401900; AB19847; 6-chloranyl-2-piperazin-1-yl-quinoline; Quinoline,6-chloro-2-(1-piperazinyl)-; AJ-83656; AX8029614; KB-248323; DB-075405; FT-0719429; Z-5014
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 247.72 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 2.6 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||


